Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma.
Pancreatic adenocarcinoma is one of the deadliest cancers with poor survival and limited treatment options. Immunotherapy is an attractive option for this cancer that needs to be further developed. Tumours have evolved a variety of mechanisms to suppress host immune responses. Understanding these responses is central in developing immunotherapy protocols. The aim of this study was to investigate potential immune suppressor mechanisms that might occur during development of pancreatic tumours. Myeloid-derived suppressor cells (MDSC) from mice with spontaneous pancreatic tumours, mice with premalignant lesions as well as wild-type mice were analysed. An increase in the frequency of MDSC early in tumour development was detected in lymph nodes, blood and pancreas of mice with premalignant lesions and increased further upon tumour progression. The MDSC from mice with pancreatic tumours have arginase activity and suppress T-cell responses, which represent the hallmark functions of these cells. Our study suggests that immune suppressor mechanisms generated by tumours exist as early as premalignant lesions and increase with tumour progression. These results highlight the importance of blocking these suppressor mechanisms early in the disease in developing immunotherapy protocols.
Zhao
Fei
F
Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.
Obermann
Sonja
S
von Wasielewski
Reinhard
R
Haile
Lydia
L
Manns
Michael P
MP
Korangy
Firouzeh
F
Greten
Tim F
TF
D000230:Adenocarcinoma / Q000276:immunology* / Q000473:pathology; D000818:Animals; D001119:Arginase / Q000378:metabolism; D039481:CD11b Antigen / Q000032:analysis; D002478:Cells, Cultured; D004195:Disease Models, Animal; D007108:Immune Tolerance / Q000276:immunology; D016130:Immunophenotyping; D008198:Lymph Nodes / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D022423:Myeloid Cells / Q000276:immunology*; D009368:Neoplasm Transplantation; D010179:Pancreas / Q000276:immunology; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000473:pathology; D011230:Precancerous Conditions / Q000276:immunology / Q000473:pathology; D013154:Spleen / Q000276:immunology
D039481:CD11b Antigen; D001119:Arginase
J Immunol. 2009 Jan 1;182(1):216-24
19109152
Blood. 2008 Apr 15;111(8):4233-44
18272812
Gastroenterology. 1998 Nov;115(5):1254-62
9797382
J Immunol. 2005 Jan 15;174(2):636-45
15634881
Blood. 2003 Sep 15;102(6):2138-45
12750171
Annu Rev Immunol. 2007;25:267-96
17134371
J Immunol. 2008 Oct 15;181(8):5791-802
18832739
J Exp Med. 2008 Sep 29;205(10):2235-49
18809714
Cancer Res. 2006 Jan 1;66(1):508-16
16397267
Nat Rev Cancer. 2005 Jun;5(6):459-67
15905855
Gastroenterology. 2002 Dec;123(6):2052-63
12454861
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Immunol. 2008 Sep 1;181(5):3116-25
18713982
J Immunol. 2004 Jun 1;172(11):6558-67
15153470
J Clin Invest. 2006 Oct;116(10):2777-90
17016559
Cancer Res. 2007 Oct 1;67(19):9518-27
17909062
J Clin Invest. 2007 May;117(5):1137-46
17476343
Cancer Res. 2006 Jan 1;66(1):95-106
16397221
Curr Opin Immunol. 2004 Apr;16(2):143-50
15023405
Semin Cancer Biol. 2006 Feb;16(1):53-65
16168663
Genes Dev. 2001 Feb 1;15(3):286-93
11159909
Immunol Rev. 2008 Apr;222:162-79
18364001